CCHT(SZ:000661) Zheng Quan Shi Bao Wang·2025-10-21 12:47Core Insights - Changchun High-tech has received multiple approvals for clinical trials of its innovative drug candidates, indicating a strong pipeline and commitment to research and development [1][2][3][4] Group 1: Drug Approvals - Changchun Jinsai Pharmaceutical has received a notice from the National Medical Products Administration (NMPA) for the clinical trial application of GenSci142 capsules, targeting Gardnerella bacteria with advantages such as rapid action and low resistance risk [1] - The company’s subsidiary, Changchun Baike Biotechnology, has also received approval for a trivalent influenza virus split vaccine (BK-01 adjuvant) aimed at individuals aged 60 and above, enhancing immune response [1] - GenSci139, a bispecific antibody-drug conjugate targeting EGFR and HER2, has been approved for clinical trials in advanced solid tumor patients, showcasing its strong tumor-killing potential and safety profile [2] - GenSci143 has received acceptance for clinical trials from the FDA, designed to treat various solid tumors with a dual-target approach and high efficacy [3] Group 2: Research and Development Focus - The company has significantly increased its R&D investments, focusing on cutting-edge innovations and accelerating international transformation [4] - Artificial intelligence (AI) is being utilized to enhance drug research efficiency, particularly in precision targeting and drug design [4] - The company is developing a diverse pipeline of innovative drugs across multiple disease areas and treatment modalities, aiming for high competitiveness and differentiation [4]